Esophageal Diseases  >>  brivanib alaninate (BMS-582664)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
brivanib alaninate (BMS-582664) / BMS
NCT00633789 / 2008-000087-16: Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Checkmark P2 data-ESMO
Sep 2012 - Sep 2012: P2 data-ESMO
Checkmark Data
Jun 2011 - Jun 2011: Data
Completed
2
597
US, Canada, Europe, RoW
brivanib, BMS-582664, Placebo
Bristol-Myers Squibb
Advanced Non-small Cell Lung Cancer, Transitional Cell Carcinoma, Soft Tissue Sarcoma, Gastric/Esophageal Adenocarcinoma, Pancreatic Cancer Including Ampulla of Vater
02/12
12/12

Download Options